Antiproliferative Potentials of Zingiber officinale in Testosterone Induced Prostate Hyperplastic Albino Wister Rats

Main Article Content

U. A. Obisike
N. Boisa
E. O. Nwachuku
N. Nduka

Abstract

Aims: The present study evaluated the anti-proliferative potential of Zingiber officinale - Zo (Ginger) rhizome and Dutasteride (Avodart) singly and in combination on testosterone propionate (TP) induced benign prostatic hyperplastic (BPH) male albino wistar rats.

Study Design: This study is an interventional study.

Place and Duration of Study: This study was conducted at the Department of Pharmacology, University of Port Harcourt, between April and September, 2019.

Methodology: A total of 70 adult male albino wistar rats that weighed between 170-200 g were used for this study. They were fed with commercial rat diet and clean drinking water. Aqueous and ethanolic extracts of Ginger rhizome were prepared using the maceration method. BPH was induced in rats after they were subjected to bilateral orchiectomy by daily injections of TP (4 mg/kg b.wt.sc.). Rats were treated with 500 or 1500 mg/kg b.wt. of aqueous or ethanoI extracts of Zo rhizome, dutasteride or in combination. Administration of extracts was done by gavage. Plasma prostate specific antigen (PSA) was analysed using sandwich ELISA Kits by Shanghai Korain Biotech Co., Ltd, China, prostatic weight (PW) was determined using a weighing balance while rat prostatic volume (PV) was calculated from measured prostatic length, breath and height. Prostatic indices (PI) and percentage prostatic growth inhibition (Percent. I) by the extracts were calculated. Statistical analysis was done using SPSS version 22.0 of Windows Stat Pac and p values <0.05 were considered statistically significant.

Results: The results showed that 500 and 1500 mg/kg b.wt. of Zo rhizome administered orally after exogenous injection of TP and BPH had been established for 15 days, significantly decreased (p=0.000) mean PV, PW, PI and PSA levels in treated rat groups compared with BPH induced rat groups. Both doses of the Zo extracts individually and in combination with dutasteride also markedly decreased (p=0.000) mean PV, PW, PI and PSA, indicating that there could be synergistic interaction between the Zo and the drug. Individual extract and in combination with dutasteride also produced high percentage inhibition of the prostate. Simultaneous administration of aqueous and ethanolic extracts of Zo rhizome with TP injection for 30 days also showed anti-proliferative qualities, although the effects were statistically not better than values for treatments done when BPH was established before treatment. Ethanolic extracts of both Zo rhizome produced better effects compared to the aqueous extracts.

Conclusion: From the findings, we conclude that ginger rhizome could reduce and inhibit testosterone-induced hyperplasia of the prostate in albino wistar rats and is suggested for further studies, especially in humans.

Keywords:
Antiproliferative, Zingiber officinale, testosterone, prostate hyperplastic, albino rats

Article Details

How to Cite
Obisike, U. A., Boisa, N., Nwachuku, E. O., & Nduka, N. (2020). Antiproliferative Potentials of Zingiber officinale in Testosterone Induced Prostate Hyperplastic Albino Wister Rats. International Research Journal of Oncology, 3(2), 20-30. Retrieved from https://journalirjo.com/index.php/IRJO/article/view/30127
Section
Original Research Article

References

Oesterling JE. Benign prostatic hyperplasia: A review of its histogenesis and natural history. The Prostate. 1996;29 (6):67–73.

Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age, The J of Urol. 2014;132(3):474–79.

O’Leary MP. Lower urinary tract symptoms/benign prostatic hyperplasia: maintaining symptom control and reducing complications. Urology. 2003;62(3):15–23.

Wasserman NF. Benign prostatic hyperplasia: A review and ultrasound classification, Radiologic Clin. of N Am. 2006;44(5):689–10.

Izumi K, Li L, Chang C. Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer. Clinical Investigations (London). 2014;4: 935 950.

Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Europen Journal of Urol. 2014;51:1202 16.

Shoskes DA. Phytotherapy in chronic prostatitis. Urology. 2000;60(6):35 37.

Demin G, Yingying Z. Comparative antibacterial activities of crude polysaccharides and flavonoids from Zingiber officinale and their extraction. American Journal of Tropical Medicine. 2010;5:235–38.

Srinivasan K. Antioxidant potential of spices and their active constituents, Critical Reviews in Food Science and Nutrition. 2014;54(3):352–72.

National Institute of Health. Guide for the Care and Use of Laboratory Animals prepared by the National Institute of Health; 1985.

Obisike UA, Nwachuku EO, Boisa N, Nduka N. Determination of exogenous testosterone propionate dose for induction of benign prostatic hyperplasia in rat model. European Journal of Biomedical and Pharmaceutical Sciences. 2019;6(13):141-47.

Van Coppenolle F, Le Bourhis X, Carpentier F, Delaby G, Cousse H, Raynaud JP, Dupouy JP, Prevarskaya N. Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon) on rat prostate hyperplasia induced by hyperprolactinemia: Comparison with finasteride. Prostate. 2000;43(1):49-58.

Center for Drug Evaluation and Research. U.S. Department of Health and Human Services Food and Drug Administration: Conversion of Human and Animal doses for chemical used for pre-clinical studies; 2005.

McCarthy U, Distaburd RT, Larry DG. Novel estimation of plasma protein. Journal of Diagnostic Medicine. 1983;232:345-41.

Surh YJ. Molecular mechanisms of chemopreventive effects of selected dietary and medicinal phenolic substances. Mutational Research. 1999;428(1-2):305–27.

Shukla Y, Prasad S., Tripathi C, Singh M, George J. In vitro and in vivo modulation of testosterone mediated alterations in apoptosis related proteins by [6]-gingerol. Molecular and Nutritional Food Research. 2007;51:1492–1502.

Prasanthi K, Koib M, Joihi KL. Ginger and apoptosis. New England Journal of Medicine. 2012;355(3)34-38.

Roslin JT, Anupam B. Terpenoids as potential chemopreventive and therapeutic agents in liver cancer. World Journal of Hepatology. 2011;3(9):228– 49.

Krell J, Stebbing J. Ginger: the root of cancer therapy? Lancet of Oncology. 2012; 13:235–36.

Rhode JM, Huang J, Fogoros S, Tan L, Zick S, Liu JR. Ginger induces apoptosis and autophagocytosis in ovarian cancer cells. Washington, DC; 2006.

Eleazuu C, Eleazu K, Kalu W. Management of benign prostatic hyperplasia: Could dietary polyphenols be an alternative to existing therapies? Frontals of Pharmacology. 2017;8:234-39.

Alberto B, Umberto C, Nazareno S, Andrea G, Andrea S, Marco B. A review on aetiology of Benign prostatic hyperplasia. England Journal of Urology. 2009;343(3):434-41.

Liu S, Bai M, Ji X, Zhang Y, Miao M. Effect of total alkaloids extracted from Leonuri Herba on mice benign prostate hyperplasia. Chinese Journal of Experimental Traditional Medical Formulae. 2011;23:65-72.

Chen XW, Sneed KB, Pan SY, Cao C, Kanwar JR, Chew H, Zhou SF. Herb-drug interactions and mechanistic and clinical considerations. Current Drug and Metabolism. 2012;13:640–51.

Colalto C. Herbal interactions on absorption of drugs: Mechanisms of action and clinical risk assessment. Pharmacological Research. 2010;62:207–27.

Singh R, Singh MK, Chandra LR. In vitro antioxidant and free radical scavenging activity of Macrotyloma uniflorum (Gahat dal) from Kumauni region. Journal of Fundamental and Applied Science. 2012; 1:7-10.

McConnell, K, Jo G, Lam F. Benign prostatic hyperplasia. Journal of Urology. 1992;85(5):56-9.

Ozbay T, Nahta R. Delphinidin inhibits HER2 and Erk1/2 signaling and suppresses growth of HER2-overexpressing and triple negative breast cancer cell lines. Breast Cancer. 2011;5:143-54.